title: [Local therapy and adjuvant interferon therapy in genital papilloma virus infections].
abstract: OBJECTIVE
  Is it possible to reduce the recurrence rates of HPV-positive genital tract lesions by systemic interferon alfa-2a in addition to local therapy?
  
  
  METHODS
  Thirty-three of 63 patients with first manifestation of papillomavirus infection or monolocal manifestation were treated by local therapy. The other 30 patients with recurrent or multiorgan infections received 3 courses with 12 x 10(6) IU interferon alfa-2a subcutaneously.
  
  
  RESULTS
  For the remaining 47 patients (16 were lost to follow-up) we found a significantly lower recurrence rate of 21% (5 of 24) in the group of interferon-treated patients compared to 52% (12 of 23) of patients treated without interferon.
  
  
  CONCLUSIONS
  The systemic treatment of HPV-positive genital tract lesions with interferon alfa-2a in addition to CO2 laser surgery or cone biopsy seems to reduce the recurrence rates of HPV-positive lesions.
authors.affiliation: Universitätsfrauenklinik Würzburg, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Backe
authors.forename: T
authors.initials: T
authors.lastname: Roos
authors.forename: H
authors.initials: H
authors.lastname: Kaesemann
authors.forename: J
authors.initials: J
authors.lastname: Martius
authors.forename: M
authors.initials: M
authors.lastname: Ott
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002584:Cervix Uteri / Q000473:pathology; D002648:Child; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000473:pathology / Q000628:therapy*; D005260:Female; D005833:Genital Neoplasms, Female / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D053685:Laser Therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D027383:Papillomaviridae / Q000187:drug effects; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy; D014625:Vaginal Neoplasms / Q000473:pathology / Q000628:therapy; D014846:Vulvar Neoplasms / Q000473:pathology / Q000628:therapy; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000628:therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins